| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Hematology-Oncology, Department of Medicine [C. R. C., Z. Z-G.], and National Biomedical ESR Center [J. N., W. E. A.], Medical College of Wisconsin, Milwaukee, Wisconsin 53226
We have shown that transferrin-gallium (Tf-Ga) blocks DNA synthesis through inhibition of cellular iron incorporation and a diminution in the activity of the iron-dependent M2 subunit of ribonucleotide reductase. To examine the mechanisms of drug resistance to gallium, we developed a subline of HL60 cells (R cells) which is 29-fold more resistant to growth inhibition by gallium nitrate than the parent line (S cells). R cells displayed a 2.5-fold increase in transferrin (Tf) receptor expression, without a change in receptor affinity for Tf. The uptake and release of 67Ga were similar for both S and R cells. The uptake of 59Fe-Tf by S cells was inhibited by gallium nitrate over 2448 h of incubation. In contrast, 59Fe-Tf uptake by R cells, although initially inhibited by gallium nitrate at 24 h, was no longer inhibited at 48 h of incubation. 59FeCl3 uptake by R cells was significantly greater than that of S cells, regardless of the time in culture. Despite the increase in 59Fe uptake by R cells, the ferritin content of these cells was lower than that of S cells. The ribonucleotide reductase electron spin resonance signal of R cells was comparable to that of S cells. R cells were not cross-resistant to Adriamycin, vincristine, cis-platinum or hydroxyurea. Resistance to gallium nitrate in this subline of HL60 cells results primarily from the ability of cells to overcome the gallium-induced block in iron incorporation. In addition, intracellular iron in R cells appears to traffic preferentially to a non-ferritin compartment.
1 This work was supported by USPHS Grant RO1 CA41740 from the National Cancer Institute to C. R. C.
2 To whom requests for reprints should be addressed, at Division of Hematology/Oncology, Medical College of Wisconsin, 8700 W. Wisconsin Avenue, Milwaukee, WI 53226.
Received 10/27/89.
Revised 1/16/90.
This article has been cited by other articles:
![]() |
N. P. Davies, Y. S. Rahmanto, C. R. Chitambar, and D. R. Richardson Resistance to the Antineoplastic Agent Gallium Nitrate Results in Marked Alterations in Intracellular Iron and Gallium Trafficking: Identification of Novel Intermediates J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 153 - 162. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Heffeter, M. Pongratz, E. Steiner, P. Chiba, M. A. Jakupec, L. Elbling, B. Marian, W. Korner, F. Sevelda, M. Micksche, et al. Intrinsic and Acquired Forms of Resistance against the Anticancer Ruthenium Compound KP1019 [Indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A) J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 281 - 289. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. M. Brown, M. C. Kennedy, W. E. Antholine, R. S. Eisenstein, and W. E. Walden Detection of a [3Fe-4S] Cluster Intermediate of Cytosolic Aconitase in Yeast Expressing Iron Regulatory Protein 1. INSIGHTS INTO THE MECHANISM OF Fe-S CLUSTER CYCLING J. Biol. Chem., February 22, 2002; 277(9): 7246 - 7254. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |